N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
N/A N=360 Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition
Menopausal Syndrome
Primary: Change From Baseline in Menopause Rating Scale Total Score — 6.3; 4.5 units on a scale — p=0.05
Phase 2 N=24 A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
Menopause · Multiple Sclerosis
Primary: Hot Flash Related Daily Interference Scale (HFRDIS) Score — 4; 9 score on a scale
Phase 2 N=374 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
Menopause Hot Flashes
Primary: Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12 — -1.92; -2.75; -2.75; -1.39 VMS per day
N/A N=38 Reducing the Experience of Menopausal Symptoms Through Temperature
Hot Flashes · Menopause
Primary: Hot Flash Diary — 9 number of hot flashes per week
N/A N=410 MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making
Menopause · Premenopause · Postmenopause
Primary: Perceived Quality of Information — 4.1; 3.7 score on a scale — p=<.001
Phase 3 N=189 Progesterone for Perimenopausal Night Sweats
Hot Flushes · Night Sweats
Primary: Vasomotor Symptoms (VMS)/ VMS Score - at 12 Weeks — 5.5; 7.1 Units of Vasomotor Symptom Score
Phase 2 N=102 Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 8 — 82.44; 83.18; 37.3; 28.5 Hot flashes — p=0.0177
N/A N=32 Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
Menopause · Hot Flashes · Vasomotor Disturbance
Primary: Tolerability of Gabapentin — 22; 4 Participants
Phase 3 N=943 Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4 — -3.9; -5.6; -6.0; -6.0 Number of events — p=<0.01
N/A N=90 Electro-acupuncture for Menopausal Transition Symptoms
Menopause
Primary: Change of Average 24 h Hot Flash Score From Baseline — -2.29; -0.71; -0.78; -0.71 Scores on a scale
Phase 4 N=29 Impact of Hot Flashes on Sleep and Mood Disturbance
Menopause · Depression · Hot Flashes
Primary: Percent Change in Wake After Sleep Onset (WASO) — 62 percent change — p=0.007
Phase 2 N=169 Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
Menopause
Primary: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) — 73.5; 69.5; 70.4; 67.9 Number of MSVS/2 weeks — p=0.5730
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
N/A N=401 Measuring Quality of Decisions About Treatment of Menopausal Symptoms
Menopause
Primary: Menopause Knowledge — 51.3; 55.8 Percentage (0-100%) — p=0.01
N/A N=1,036,294 A Study to Learn More About the Menopausal Hormone Therapies in Korea
Menopause · Bone Demineralization
Primary: Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year — 786616; 787425; 791890; 818749 Participants
Phase 4 N=22 Duloxetine for Menopausal Depression
Depression · Menopause · Vasomotor Symptoms
Primary: Change in Depression Scores as Measured by the Hamilton Rating Scale for Depression — -7.5 units on a scale
Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
Phase 3 N=735 Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Vasomotor Symptoms · Hot Flashes
Primary: Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) — -54.515; -54.125; -44.389; -30.020 Hot Flushes per week — p=<0.0001
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Phase 4 N=157 Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women
Nocturnal Vasomotor Symptoms
Primary: Mean Change in Average Frequency of Awakenings Due to Sleep-time Hot Flashes — -19.54; -20.55; -15.99 Awakenings
Phase 3 N=248 Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
Menopause · Osteoporosis · Osteopenia
Primary: Change From Baseline in Bone Mineral Density — 1.146; 1.132 g/cm2
Phase 3 N=396 A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]). — 13.38; 14.26; -7.48; -4.37 Hot Flashes per day…
Phase 3 N=501 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.72; -5.53; -6.26 VMS per day — p=<0.001
Phase 3 N=454 Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day — -5.32; -6.19; -4.76; -8.44 Vasomotor symptoms per day — p=<0.0001
Phase 3 N=570 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12. — 10.83; 10.90; -4.13; -2.71 Hot flashes per day — p=<0.0001
N/A N=187 Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
Hot Flashes
Primary: Hot Flash Frequency — 27.19; 68.26; 19.44; 62.32 hot flashes per week
Phase 3 N=527 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Hot Flashes
Primary: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4 — -3.32; -5.19; -5.39 VMS per day — p=<0.001
Phase 3 N=945 Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
Postmenopausal Symptoms · Menopause · Vasomotor Symptoms
Primary: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4 — 12.1; 12.2; 12.6; 12.3 Events per day — p=<0.01